Ven­ture in­vest­ing with­out the GSK tie-up? Sime­on George and the SR One team score a $600M fund to pave the way for­ward

Over the past year, Sime­on George has seen the mar­ket chill for biotech, scram­bled a cri­sis team through a har­row­ing week­end as SVB’s col­lapse threat­ened com­pa­nies in its port­fo­lio and forced them to re­work their time­line on sup­port and to re­think his syn­di­cates.

And the CEO is still com­ing back with a new fund at SR One that is sub­stan­tial­ly larg­er than the first they as­sem­bled in their break­away move from the in­vest­ment arm role they played at GSK.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER